The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity
Open accessPublished version of a preprint
Abstract
The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity 1,2. The impact of genetic variability of GLP1R on receptor function and its association with metabolic traits are unclear with conflicting reports. Here, we show an unexpected diversity of phenotypes ranging from defective cell surface expression to complete or pathway-specific gain of function (GoF) and loss of function (LoF), after performing a functional profiling of 60 GLP1R variants across four signalling pathways. The defective insulin secretion of GLP1R LoF variants is rescued by allosteric GLP1R ligands or high concentrations of exendin-4/semaglutide in INS-1 823/3 cells. Genetic association studies in 200,000 participants from the UK Biobank show that impaired GLP1R cell surface expression contributes to poor glucose control and increased adiposity with increased glycated haemoglobin A1c and body mass index. This study defines impaired GLP1R cell surface expression as a risk factor for traits associated with type 2 diabetes and obesity and provides potential treatment options for GLP1R LoF variant carriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in vitro functional assays of the identified mutations only investigated GLP-1-dependent insulin secretion”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [103]
In the citing paper
“it identified rare loss-of-function mutations which were associated with increased adiposity in a 200 000-participant UK BioBank cohort (103).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Proceedings of the National Academy of Sciences
Richards, J. W. (1915) · Science · doi:10.1126/science.42.1074.161 · Cited by 13,983
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 2×
“…on GLP1R signalling from intracellular locations, on the recruitment of β-arr1, known to be also involved in insulin secretion and beta cell apoptosis 25,26 , and on physiological functions of GLP1R other than insulin secretion, such as beta cell proliferation or inhibition of food intake 1 .”
BackgroundClinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
An Evolutionary Trace Method Defines Binding Surfaces Common to Protein Families
Lichtarge, O., Bourne, H. R., & Cohen, F. E. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0167 · Cited by 1,195 · cited 2×
“…selected 34 rare missense GLP1R variants, (i) which are predicted to be of moderate-to-high impact based on their evolutionary action (EA) scores 7,8 , (ii) for which literature data were available on the functional consequences of alanine mutations 9 and (iii) which were located in transmembrane…”
BackgroundMethodSelf-citationRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 1×
“Carriers of these LoF GLP1R variants might thus benefit not only from the latest generations of GLP1R agonists including unimolecular GLP1R/GIPR dual agonists 21 , but also from recently developed GLP1R PAMs 22,23 .”
BackgroundAn abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people
Nelson, M. R., Wegmann, D., Ehm, M. G., Kessner, D., St. Jean, P., Verzilli, C., Shen, J., Tang, Z., Bacanu, S.-A., Fraser, D., et al. (2012) · Science · doi:10.1126/science.1217876 · Cited by 647
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · cited 1×
“The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity 1,2 .”
BackgroundRare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes
The Meta-Analysis of Glucose and Insulin-Related Traits Consortium (MAGIC), Bonnefond, A., Clément, N., Fawcett, K., Yengo, L., Vaillant, E., Guillaume, J.-L., Dechaume, A., Payne, F., Roussel, R., et al. (2012) · Nature Genetics · doi:10.1038/ng.1053 · Cited by 363 · cited 1×
“8), highlighting the importance of in vitro analyses as we show here and in previous functional genetics-based studies 13–15 , although the number of carriers was lower.”
BackgroundSelf-citation
Cited by
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“In a recent systematic review and meta-analysis involving 32 relevant studies, no clear effect of BMI on GLP-1 responses was observed, but it was concluded that heterogeneity due to small sample sizes, poor matching of groups and inconsistent methodology precluded a clear conclusion 82 .”
InfluentialKizilkaya, H. S., Sørensen, K. V., Madsen, J. S., Lindquist, P., Douros, J. D., Bork‐Jensen, J., Berghella, A., Gerlach, P. A., Gasbjerg, L. S., Mokrosiński, J., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01061-4 · Cited by 62
“All phenotypes, including BMI (#21001), body fat percentage (#23099), waist circumference (#48), systolic blood pressure (#93), diastolic blood pressure (#94), obesity/ E66 (#130792), hypertension/I10 (#131286) and non-insulin-dependent (type II) diabetes mellitus/E11 (#130708) were pre-processed with PHE-SANT 63 and…”
InfluentialObesity: exploring its connection to brain function through genetic and genomic perspectives
Saeed, S., Bonnefond, A., & Froguel, P. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02737-9 · Cited by 60
Self-citationStructural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Metadata
- Authors
- Gao, W., Liu, L., Huh, E., Gbahou, F., Cecon, E., Oshima, M., Houzé, L., Katsonis, P., Hegron, A., Fan, Z., Hou, G., Charpentier, G., Boissel, M., Derhourhi, M., Marre, M., Balkau, B., Froguel, P., Scharfmann, R., Lichtarge, O., Dam, J., Bonnefond, A., Liu, J., & Jockers, R.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Baylor College of Medicine (US)
- Huazhong University of Science and Technology (CN)
- Centre d'Etudes et de Recherches pour l'Intensification du Traitement du Diabète (FR)
- Inserm (FR)
- Université Paris-Sud (FR)
- Corresponding author
- Liu, Jianfeng
- Jockers, Ralf
- ORCID
- Gao, Wenwen
- Liu, Lei
- Huh, Eunna
- Gbahou, Florence
- Cecon, Erika
- Oshima, Masaya
- Katsonis, Panagiotis
- Hegron, Alan
- Fan, Zhiran
- Charpentier, Guillaume
- Boissel, Mathilde
- Derhourhi, Mehdi
- Marre, Michel
- Balkau, Beverley
- Froguel, Philippe
- Scharfmann, Raphael
- Lichtarge, Olivier
- Dam, Julie
- Bonnefond, Amélie
- Liu, Jianfeng
- Jockers, Ralf
- Venue
- Nature Metabolism
- Published
- 2023-09-14
- Volume
- 5
- Issue
- 10
- Pages
- 1673-1684
- ISSN
- 2522-5812 (ISSN-L)
- PMC
- PMC11610247
- OpenAlex
- W4386740781
- Cited by
- 56
- References
- 39
- Citations by year
- 2026: 20 · 2025: 16 · 2024: 19 · 2023: 1
- FWCI
- 11.42
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Metabolism (publishedVersion)
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion, cc-by)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- European Commission (ANR-10-LABX-46)
- Agence Nationale de la Recherche (ANR-18-IBHU-0001, ANR‐10‐LABX‐46, ANR‐2011‐BSV1‐012‐01, ANR-10-INBS-0009, ANR-11-LABX-0071, ANR‐10‐EQPX‐07‐01, 10-LABX-46, ANR18, IDEX-0005, ANR-2011-META, ANR-11-IDEX, ANR-21-CE18-0023, ANR-10, ANR-10-INBS-009, ANR-11-IDEX-0005, ANR-10-EQPX)
- Institut National de la Santé et de la Recherche Médicale
- National Natural Science Foundation of China (81720108031, 2021ZD0203302, 2018YFA0507003, 81872945, 31721002)
- Centre National de la Recherche Scientifique
- Conseil Régional Hauts-de-France
- National Institutes of Health (-0001)
- Medical Research Council (MC_PC_17228)
- National Institute of General Medical Sciences (R01GM066099)
- H2020 European Research Council (715575)
- FP7 Ideas: European Research Council (294785)
- CHIST-ERA
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- GLP-1 receptor, genetic variants, cell surface expression, loss of function, gain-of-function, insulin secretion, glucose homeostasis, adiposity, type 2 diabetes, obesity, cAMP signaling, exendin-4, semaglutide, allosteric ligands, glycated haemoglobin A1c, body mass index
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Humans, Insulin, Obesity, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity. https://app.cochat.ai/papers/10.1038/s42255-023-00889-6
- The paper
- Gao, W., Liu, L., Huh, E., Gbahou, F., Cecon, E., Oshima, M., Houzé, L., Katsonis, P., Hegron, A., Fan, Z., Hou, G., Charpentier, G., Boissel, M., Derhourhi, M., Marre, M., Balkau, B., Froguel, P., Scharfmann, R., Lichtarge, O., . . . Jockers, R. (2023). Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity. Nature Metabolism. https://doi.org/10.1038/s42255-023-00889-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.